Previous 10 | Next 10 |
(Sourced from Idorsia) On July 16th, 2019, I shared my initial Idorsia ( IDRSF ) article, " Idorsia: A Swiss Biotech Poised for Fantastic Growth ." At the time of publication, the stock ended the day trading for $23.70 and closed on December 6th, 2019, trading for the price of $30.89 a sha...
EWING, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. Tykot is a seasoned corporate and business development executive with a proven record of su...
EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED ® , has been honored with a 2019 MarCom Platinum Award. The award...
The healthcare sector seems to be waking up over the past several weeks. Political uncertainty has been hurting healthcare stocks throughout the past year, but this uncertainty seems to be dissipating as the Presidential election approaches, which is being a major tailwind for the healthcare ...
EWING, N.J., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31 st Annual Piper Jaffray Healthcare Conference on Tuesday December 3, 2019 at 2:00 pm, Eastern Time. A li...
Image Source: Health Journals Company Thesis Antares Pharmaceuticals' ( ATRS ) XYOSTED may be one of the best testosterone therapies available when evaluated against competitors such as Aveed, Depo-Testosterone, Delatestryl, and Testopel. Considering the sector has decade-old generi...
EWING, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. (“Idorsia”) (SIX: IDIA) to develop a novel, drug-device product combining ...
Antares Pharma (NASDAQ: ATRS ) has entered into a global agreement with Idorsia Pharmaceuticals to develop a novel, drug-device product combining selatogrel, Idorsia’s potent, fast-acting and highly selective P2Y 12 receptor antagonist with the Antares subcutaneous QuickShot a...
EWING, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. (“Idorsia”) (SIX: IDIA) to develop a novel, drug-device product combining ...
EWING, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday November 20, 2019, at 11:20 am (GMT) / 6:20 am (EST) i...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...